Cardionet (BEAT) 6.91 $BEAT
BioTelemetry, Inc. Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 31, 3:05PM CDT
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the second quarter ended June 30, 2014.
Downtrend Call Working As CardioNet Stock Falls 21.1% (BEAT)
Comtex SmarTrend(R) - Tue Jul 29, 4:49PM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 4 months, CardioNet has returned 21.09% as of today's recent price of $7.37.
BioTelemetry, Inc. to Release Second Quarter 2014 Earnings Results on July 31, 2014
GlobeNewswire - Tue Jul 22, 12:15PM CDT
BioTelemetry, Inc. (Nasdaq:BEAT) will release its second quarter 2014 earnings on Thursday, July 31, 2014 at 4:00 PM Eastern Time.
CardioNet Shares Down 27.7% Since SmarTrend's Sell Call (BEAT)
Comtex SmarTrend(R) - Tue Jul 22, 10:59AM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 3 months, CardioNet has returned 27.73% as of today's recent price of $6.75.
mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis to 2019
M2 - Tue Jul 22, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f8tjcf/mhealth) has announced the addition of the "mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" report to their offering. According to The Center for Technology and Aging, the U.S. healthcare system could reduce the cost of healthcare expenditure by approximately USD 200 billion in the next 25 years through the implementation of remote patient monitoring technologies. Hence, this report is focused towards identifying the current scenario as well as the future market potential for mHealth monitoring and diagnostic devices, globally, with a special focus on medical devices like smartphones and tablets. The mHealth monitoring and diagnostic devices market has been segmented into seven major product types, namely, glucose monitors, blood pressure monitors, pulse oximeters, cardiac monitors, sleep apnea monitors, multi-parameter monitoring devices and other monitoring devices (fetal monitors, neurological monitors, asthma monitoring devices). These monitors are used for monitoring and diagnosing health and wellness of a patient via connectivity with the smartphones or tablets that enable data transfer to healthcare professionals via Bluetooth, NFC, Wi-Fi or USB stick. Of all the above mentioned monitoring and diagnostic devices, glucose monitors have been anticipated as the fastest growing segment for the forecast period 2013 to 2019, at a CAGR of 49.4%. According to the International Diabetes Federation (IDF), the number of people suffering globally from diabetes is around 392 million in 2013 and is expected to rise to 592 million by 2035. Hence, fastest growth rate of this segment is identified on the basis of year-on-year growth of diabetic patients globally and rising demand for invasive and minimally invasive glucose monitoring devices. In addition, global increase in number of smartphones and turnaround innovations in the mobile health devices, owing to improved technology are other important drivers of this market. Multi-parameter monitoring devices are also expected to witness significant growth rate in near future due to increasing awareness about health and fitness in developed countries. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global mHealth Monitoring and Diagnostic Medical Devices Market, by Product Type Chapter 5 Global mHealth Monitoring and Diagnostic Medical Devices Market, by Geography Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Bayer HealthCare AG - BioTelemetry, Inc. (CardioNet, Inc.) - Boston Scientific Corporation - DexCom, Inc. - Dr?ger AG - F. Hoffmann-La Roche Ltd. - FitBit, Inc. - Fora Care Inc. - iHealth Labs, Inc. - Johnson & Johnson - LifeWatch AG - Masimo Corporation - Medisana AG - Medtronic, Inc. - Nonin Medical, Inc. - Omron Healthcare, Inc. - Withings, Inc. For more information visit http://www.researchandmarkets.com/research/f8tjcf/mhealth
High Prevalence of Cardiovascular Diseases Drives the Market for Remote Cardiac Monitoring, According to New Trend Report Published by Global Industry Analysts, Inc.
PRWeb - Mon Jul 14, 7:14AM CDT
Follow us on LinkedIn - Remote cardiac monitoring involves the use of communication technologies for continuous monitoring of cardiac patients. An evolutionary offshoot of e-health systems and telemedicine, remote cardiac monitoring enables home electrocardiographic (ECG) monitoring of individuals who are either at a risk of developing arrhythmias or with suspected cardiac arrhythmias. Remote cardiac monitoring systems include wearable biomedical sensors designed to be either implanted or worn externally, which record patient information both intermittently and continuously. These systems incorporate a remote communication device that receives vital data from implants, and transmits the information through a mobile telephone or landline network to a remote monitoring service center or a secure server. The information is securely encrypted to ensure patient confidentiality and includes stored electrograms and arrhythmia episode reports, along with status of implanted device integrity. Demand for remote cardiac monitoring systems and services is being driven by the growing focus on reducing the cost of hospitalization.
CardioNet Down 23.4% Since SmarTrend Downtrend Call (BEAT)
Comtex SmarTrend(R) - Tue Jul 08, 9:06AM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 3 months, CardioNet has returned 23.45% as of today's recent price of $7.15.
CardioNet Has Returned 23.8% Since SmarTrend Recommendation (BEAT)
Comtex SmarTrend(R) - Fri Jun 27, 4:59PM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 3 months, CardioNet has returned 23.77% as of today's recent price of $7.12.
18.3% Return Seen to Date on SmarTrend CardioNet Call (BEAT)
Comtex SmarTrend(R) - Fri Jun 20, 11:10AM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 2 months, CardioNet has returned 18.31% as of today's recent price of $7.63.
Shares of BEAT Down 21.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 13, 9:38AM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 2 months, CardioNet has returned 21.31% as of today's recent price of $7.35.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Jun 11, 5:30AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BioTelemetry, Inc. Announces Major Advancements in Research Services
GlobeNewswire - Thu Jun 05, 11:19AM CDT
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Cardiocore, its research services subsidiary, acquired the assets of RadCore Lab, LLC ("RadCore"
, an imaging core lab serving the biopharmaceutical and medical device research market. This acquisition broadens the Company's cardiac imaging offerings and adds new oncology, musculoskeletal and neurological imaging capabilities, supported by a state-of-the-art, cloud-based analysis platform. While this acquisition provides growth potential, it is not expected to have a material impact on the Company's 2014 results of operation.
26.4% Return Seen to Date on SmarTrend CardioNet Call (BEAT)
Comtex SmarTrend(R) - Thu May 22, 11:01AM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 1 month, CardioNet has returned 26.45% as of today's recent price of $6.87.
CardioNet Shares Up 17.8% Since SmarTrend's Buy Recommendation (BEAT)
Comtex SmarTrend(R) - Tue Apr 01, 9:59AM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 2 months, CardioNet has returned 17.80% as of today's recent price of $10.39.
BioTelemetry, Inc. Announces the Acquisition of the Cardiac Patient Services Business of Biomedical Systems, Corp.
GlobeNewswire - Thu Mar 20, 7:14AM CDT
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that it has entered into a definitive agreement to acquire the cardiac patient services business of Biomedical Systems, Corp. ("BMS" for aggregate consideration of $8.65 million at closing. Post integration, the acquisition is expected to generate $8.0 to $9.0 million in revenue and $2.5 to $3.0 million in EBITDA on an annualized basis. The transaction is expected to close in early April.
CardioNet Up 15.5% Since SmarTrend Uptrend Call (BEAT)
Comtex SmarTrend(R) - Mon Mar 17, 5:33PM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 1 month, CardioNet has returned 15.53% as of today's recent price of $10.19.
BioTelemetry, Inc. Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 31, 3:05PM CDT
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the second quarter ended June 30, 2014.
Downtrend Call Working As CardioNet Stock Falls 21.1% (BEAT)
Comtex SmarTrend(R) - Tue Jul 29, 4:49PM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 4 months, CardioNet has returned 21.09% as of today's recent price of $7.37.
BioTelemetry, Inc. to Release Second Quarter 2014 Earnings Results on July 31, 2014
GlobeNewswire - Tue Jul 22, 12:15PM CDT
BioTelemetry, Inc. (Nasdaq:BEAT) will release its second quarter 2014 earnings on Thursday, July 31, 2014 at 4:00 PM Eastern Time.
CardioNet Shares Down 27.7% Since SmarTrend's Sell Call (BEAT)
Comtex SmarTrend(R) - Tue Jul 22, 10:59AM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 3 months, CardioNet has returned 27.73% as of today's recent price of $6.75.
mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis to 2019
M2 - Tue Jul 22, 6:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/f8tjcf/mhealth) has announced the addition of the "mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" report to their offering. According to The Center for Technology and Aging, the U.S. healthcare system could reduce the cost of healthcare expenditure by approximately USD 200 billion in the next 25 years through the implementation of remote patient monitoring technologies. Hence, this report is focused towards identifying the current scenario as well as the future market potential for mHealth monitoring and diagnostic devices, globally, with a special focus on medical devices like smartphones and tablets. The mHealth monitoring and diagnostic devices market has been segmented into seven major product types, namely, glucose monitors, blood pressure monitors, pulse oximeters, cardiac monitors, sleep apnea monitors, multi-parameter monitoring devices and other monitoring devices (fetal monitors, neurological monitors, asthma monitoring devices). These monitors are used for monitoring and diagnosing health and wellness of a patient via connectivity with the smartphones or tablets that enable data transfer to healthcare professionals via Bluetooth, NFC, Wi-Fi or USB stick. Of all the above mentioned monitoring and diagnostic devices, glucose monitors have been anticipated as the fastest growing segment for the forecast period 2013 to 2019, at a CAGR of 49.4%. According to the International Diabetes Federation (IDF), the number of people suffering globally from diabetes is around 392 million in 2013 and is expected to rise to 592 million by 2035. Hence, fastest growth rate of this segment is identified on the basis of year-on-year growth of diabetic patients globally and rising demand for invasive and minimally invasive glucose monitoring devices. In addition, global increase in number of smartphones and turnaround innovations in the mobile health devices, owing to improved technology are other important drivers of this market. Multi-parameter monitoring devices are also expected to witness significant growth rate in near future due to increasing awareness about health and fitness in developed countries. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global mHealth Monitoring and Diagnostic Medical Devices Market, by Product Type Chapter 5 Global mHealth Monitoring and Diagnostic Medical Devices Market, by Geography Chapter 6 Competitive Landscape Chapter 7 Recommendations Chapter 8 Company Profiles - Bayer HealthCare AG - BioTelemetry, Inc. (CardioNet, Inc.) - Boston Scientific Corporation - DexCom, Inc. - Dr?ger AG - F. Hoffmann-La Roche Ltd. - FitBit, Inc. - Fora Care Inc. - iHealth Labs, Inc. - Johnson & Johnson - LifeWatch AG - Masimo Corporation - Medisana AG - Medtronic, Inc. - Nonin Medical, Inc. - Omron Healthcare, Inc. - Withings, Inc. For more information visit http://www.researchandmarkets.com/research/f8tjcf/mhealth
High Prevalence of Cardiovascular Diseases Drives the Market for Remote Cardiac Monitoring, According to New Trend Report Published by Global Industry Analysts, Inc.
PRWeb - Mon Jul 14, 7:14AM CDT
Follow us on LinkedIn - Remote cardiac monitoring involves the use of communication technologies for continuous monitoring of cardiac patients. An evolutionary offshoot of e-health systems and telemedicine, remote cardiac monitoring enables home electrocardiographic (ECG) monitoring of individuals who are either at a risk of developing arrhythmias or with suspected cardiac arrhythmias. Remote cardiac monitoring systems include wearable biomedical sensors designed to be either implanted or worn externally, which record patient information both intermittently and continuously. These systems incorporate a remote communication device that receives vital data from implants, and transmits the information through a mobile telephone or landline network to a remote monitoring service center or a secure server. The information is securely encrypted to ensure patient confidentiality and includes stored electrograms and arrhythmia episode reports, along with status of implanted device integrity. Demand for remote cardiac monitoring systems and services is being driven by the growing focus on reducing the cost of hospitalization.
CardioNet Down 23.4% Since SmarTrend Downtrend Call (BEAT)
Comtex SmarTrend(R) - Tue Jul 08, 9:06AM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 3 months, CardioNet has returned 23.45% as of today's recent price of $7.15.
CardioNet Has Returned 23.8% Since SmarTrend Recommendation (BEAT)
Comtex SmarTrend(R) - Fri Jun 27, 4:59PM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 3 months, CardioNet has returned 23.77% as of today's recent price of $7.12.
18.3% Return Seen to Date on SmarTrend CardioNet Call (BEAT)
Comtex SmarTrend(R) - Fri Jun 20, 11:10AM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 2 months, CardioNet has returned 18.31% as of today's recent price of $7.63.
Shares of BEAT Down 21.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 13, 9:38AM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 2 months, CardioNet has returned 21.31% as of today's recent price of $7.35.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Jun 11, 5:30AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
BioTelemetry, Inc. Announces Major Advancements in Research Services
GlobeNewswire - Thu Jun 05, 11:19AM CDT
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Cardiocore, its research services subsidiary, acquired the assets of RadCore Lab, LLC ("RadCore"
, an imaging core lab serving the biopharmaceutical and medical device research market. This acquisition broadens the Company's cardiac imaging offerings and adds new oncology, musculoskeletal and neurological imaging capabilities, supported by a state-of-the-art, cloud-based analysis platform. While this acquisition provides growth potential, it is not expected to have a material impact on the Company's 2014 results of operation. 26.4% Return Seen to Date on SmarTrend CardioNet Call (BEAT)
Comtex SmarTrend(R) - Thu May 22, 11:01AM CDT
SmarTrend identified a Downtrend for CardioNet (NASDAQ:BEAT) on April 10th, 2014 at $9.34. In approximately 1 month, CardioNet has returned 26.45% as of today's recent price of $6.87.
CardioNet Shares Up 17.8% Since SmarTrend's Buy Recommendation (BEAT)
Comtex SmarTrend(R) - Tue Apr 01, 9:59AM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 2 months, CardioNet has returned 17.80% as of today's recent price of $10.39.
BioTelemetry, Inc. Announces the Acquisition of the Cardiac Patient Services Business of Biomedical Systems, Corp.
GlobeNewswire - Thu Mar 20, 7:14AM CDT
BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that it has entered into a definitive agreement to acquire the cardiac patient services business of Biomedical Systems, Corp. ("BMS"
for aggregate consideration of $8.65 million at closing. Post integration, the acquisition is expected to generate $8.0 to $9.0 million in revenue and $2.5 to $3.0 million in EBITDA on an annualized basis. The transaction is expected to close in early April. CardioNet Up 15.5% Since SmarTrend Uptrend Call (BEAT)
Comtex SmarTrend(R) - Mon Mar 17, 5:33PM CDT
SmarTrend identified an Uptrend for CardioNet (NASDAQ:BEAT) on February 3rd, 2014 at $8.82. In approximately 1 month, CardioNet has returned 15.53% as of today's recent price of $10.19.
